Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate

被引:38
作者
Gamsjaeger, Sonja [1 ]
Buchinger, Birgit [1 ]
Zoehrer, Ruth [1 ]
Phipps, Roger [2 ]
Klaushofer, Klaus [1 ]
Paschalis, Eleftherios P. [1 ]
机构
[1] Hanusch Hosp, Ludwig Boltzmann Inst Osteol, WGKK & AUVA Trauma Ctr Meidling, Dept Med 1, A-1140 Vienna, Austria
[2] Procter & Gamble Pharmaceut, Mason, OH USA
关键词
Teriparatide; Alendronate; Risedronate; Bone material properties; Fourier transform infrared imaging; Raman Microspectroscopy; Mineral maturity; Collagen cross-links; ILIAC CREST BIOPSIES; FTIR MICROSPECTROSCOPIC ANALYSIS; PARATHYROID-HORMONE; AMERICAN-SOCIETY; MINERAL DENSITY; TASK-FORCE; QUALITY; OSTEONECROSIS; JAW; HYDROXYAPATITE;
D O I
10.1016/j.bone.2011.08.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the present work we examined the effect of teriparatide administration following bisphosphonate treatment on bone compositional properties by Raman and Fourier Transform Infrared Imaging (FTIR) microspectroscopic analysis. Thirty two paired iliac crest biopsies (before and after 1 year teriparatide) from sixteen osteoporotic women previously treated with either Alendronate (ALN) or Risedronate (RIS) and subsequently treated 12 months with teriparatide (TPTD) were analyzed at anatomical areas of similar tissue age in bone forming areas (within the fluorescent double labels). The outcomes that were monitored and reported were mineral to matrix ratio (corresponding to ash weight), mineral maturity (indicative of the mineral crystallite chemistry and stoichiometry, and having a direct bearing on crystallite shape and size), relative proteoglycan content (regulating mineralization commencement), and the ratio of two of the major enzymatic collagen cross-links (pyridinoline/divalent). Significant differences in mineral/matrix, mineral maturity/crystallinity, and collagen cross-link ratio bone quality indices after TPTD treatment were observed, indicating a specific response of these patients to TPTD treatment. Moreover differences between ALN and RIS treated patients at baseline in the collagen cross-link ratio were observed. Since tissue areas of similar tissue age were analyzed, these differences may not be attributed to differences in bone turnover. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1160 / 1165
页数:6
相关论文
共 50 条
  • [31] Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women
    Nakamura, Yukio
    Suzuki, Takako
    Kamimura, Mikio
    Ikegami, Shota
    Murakami, Kohei
    Uchiyama, Shigeharu
    Taguchi, Akira
    Kato, Hiroyuki
    BONE RESEARCH, 2017, 5
  • [32] Five Years of Treatment with Risedronate and its Effects on Bone Safety in Women with Postmenopausal Osteoporosis
    L.-G. Ste-Marie
    E. Sod
    T. Johnson
    A. Chines
    Calcified Tissue International, 2004, 75 : 469 - 476
  • [33] Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis
    Ste-Marie, LG
    Sod, E
    Johnson, T
    Chines, A
    CALCIFIED TISSUE INTERNATIONAL, 2004, 75 (06) : 469 - 476
  • [34] Effects of 25-Hydroxyvitamin D3 Therapy on Bone Turnover Markers and PTH Levels in Postmenopausal Osteoporotic Women Treated with Alendronate
    Olmos, Jose M.
    Hernandez, Jose L.
    Llorca, Javier
    Nan, Daniel
    Valero, Carmen
    Gonzalez-Macias, Jesus
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (12) : 4491 - 4497
  • [35] Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months
    Anastasilakis, A. D.
    Polyzos, S. A.
    Makras, P.
    Gkiomisi, A.
    Bisbinas, I.
    Katsarou, A.
    Filippaios, A.
    Mantzoros, C. S.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 (05) : 1633 - 1642
  • [36] Effects of 3-and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women
    Zoehrer, Ruth
    Roschger, Paul
    Paschalis, Eleftherios P.
    Hofstaetter, Jochen G.
    Durchschlag, Erich
    Fratzl, Peter
    Phipps, Roger
    Klaushofer, Klaus
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (07) : 1106 - 1112
  • [37] RETRACTED: Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes (Retracted Article)
    Iwamoto, Jun
    Sato, Yoshihiro
    Uzawa, Mitsuyoshi
    Takeda, Tsuyoshi
    Matsumoto, Hideo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 93 (02) : 166 - 173
  • [38] Short-term risedronate treatment in postmenopausal women: Effects on biochemical markers of bone turnover
    Raisz, L
    Smith, JA
    Trahiotis, M
    Fall, P
    Shoukri, K
    DiGennaro, J
    Sacco-Gibson, N
    OSTEOPOROSIS INTERNATIONAL, 2000, 11 (07) : 615 - 620
  • [39] Bone Material Properties in Actively Bone-Forming Trabeculae in Postmenopausal Women With Osteoporosis After Three Years of Treatment With Once-Yearly Zoledronic Acid
    Gamsjaeger, Sonja
    Buchinger, Birgit
    Zwettler, Elizabeth
    Recker, Robert
    Black, Dennis
    Gasser, Juerg A.
    Eriksen, Erik F.
    Klaushofer, Klaus
    Paschalis, Eleftherios P.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (01) : 12 - 18
  • [40] Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment
    Obermayer-Pietsch, Barbara M.
    Marin, Fernando
    McCloskey, Eugene V.
    Hadji, Peyman
    Farrerons, Jordi
    Boonen, Steven
    Audran, Maurice
    Barker, Clare
    Anastasilakis, Athanasios D.
    Fraser, William D.
    Nickelsen, Thomas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 (10) : 1591 - 1600